Aquestive therapeutics provides international expansion update for anaphylm™ (epinephrine) sublingual film

Warren, n.j., july 15, 2025 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (“aquestive” or the “company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that health canada has granted the company a meeting to discuss aquestive's planned new drug submission (nds) for anaphylm™ (epinephrine) sublingual film in canada. in addition, the company has submitted an initial briefing book to the european medicines agency (ema). the company plans to submit a marketing authorization application (maa) to the ema as soon as possible.
AQST Ratings Summary
AQST Quant Ranking